Page 402 - ILAE_Lectures_2015

19. NILSSON OS, LINDHOLM TS, ELMSTEDT E, LINDBACK A, LINDHOLM TC. Fracture incidence and
bone-disease in epileptics receiving long term anticonvulsant drug treatment. Arch Orthopaed Trauma Surg
1986;105(3):146-149.

20. ANNEGERS JF, MELTON LJ, SUN CA, HAUSER WA. Risk of age related fractures in patients with
unprovoked seizures. Epilepsia 1989;30(3):348-355.

21. NEUFELD MY, VISHNE T, CHISTIK V, KORCZYN AD. Life-long history of injuries related to seizures.
Epilepsy Res 1999;34(2-3):123-127.

22. PERSSON HBI, ALBERTS KA, FARAHMAND BY, TOMSON T. Risk of extremity fractures in adult
outpatients with epilepsy. Epilepsia 2002;43(7):768-772.

23. SOUVEREIN PC, WEBB DJ, PETRI H, WEIL J, VAN STAA TP, EGBERTS T. Incidence of Fractures among
Epilepsy Patients: A Population-based Retrospective Cohort Study in the General Practice Research Database.
Epilepsia 2005;46(2):304-310.

24. VESTERGAARD P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand
2005;112(5):277-286.

25. SHEN CH, CHEN F, ZHANG YX, GUO Y, DING MP. Association between use of antiepileptic drugs and
fracture risk: A systematic review and meta-analysis. Bone 2014;64:246-253.

26. VESTERGAARD P, TIGARAN S, REJNMARK L, TIGARAN C, DAM M, MOSEKILDE L. Fracture risk is
increased in epilepsy. Acta Neurol Scand 1999;99(5):269-275.

27. AHMAD BS, HILL KD, O'BRIEN TJ, GORELIK A, HABIB N, WARK JD. Falls and fractures in patients
chronically treated with antiepileptic drugs. Neurology 2012;79(2):145-151.

28. ZACCARA G, CINCOTTA M, BORGHERESI A, BALESTRIERI F. Adverse motor effects induced by
antiepileptic drugs. Epileptic Disorders 2004;6(3):153-168.

29. POMEROY VM, HISCOCK A, COCK HR, TALLIS RC. Impact of carbamazepine on postural control in older
adults: an exploratory study. Physiotherapy 2008;94:230-235.

30. VESTERGAARD P, REJNMARK L, MOSEKILDE L. Fracture risk associated with use of antiepileptic drugs.
Epilepsia 2004;45(11):1330-1337.

31. SOUVEREIN PC, WEBB DJ, WEIL JG, VAN STAA P, EGBERTS ACG. Use of antiepileptic drugs and risk
of fractures - Case-control study among patients with epilepsy. Neurology 2006;66(9):1318-1324.

32. NICHOLAS JM, RIDSDALE L, RICHARDSON MP, GRIEVE AP, GULLIFORD MC. Fracture risk with use
of liver enzyme inducing antiepileptic drugs in people with active epilepsy: Cohort study using the General
Practice Research Database. Seizure 2013;22(1):37-42.

33. CROSLEY CJ, CHEE C, BERMAN PH. Rickets associated with long-term anticonvulsant therapy in a pediatric
outpatient poluation. Pediatrics 1975;56:52-57.

34. KUMANDAS S, KOKLU E, GUMUS H, et al. Effect of carbamezapine and valproic acid on bone mineral
density, IGF-I and IGFBP-3. J Pediatr Endocrinol Metab 2006;19(4):529-534.

35. MINTZER S, BOPPANA P, TOGURI J, DESANTIS A. Vitamin D levels and bone turnover in epilepsy patients
taking carbamazepine or oxcarbazepine. Epilepsia 2006;47(3):510-515.

36. PACK AM, MORRELL MJ, MARCUS R, et al. Bone mass and turnover in women with epilepsy on
antiepileptic drug monotherapy. Ann Neurol 2005;57(2):252-257.

37. FARHAT G, YAMOUT B, MIKATI MA, DEMIRJIAN S, SAWAYA R, FULEIHAN GEH. Effect of
antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58(9):1348-1353.

38. ANDRESS DL, OZUNA J, TIRSCHWELL D, et al. Antiepileptic drug-induced bone loss in young male
patients who have seizures. Arch Neurol 2002;59(5):781-786.

39. CETINKAYA Y, KURTULMUS YS, TUTKAVUL K, TIRELI H. The Effect of Oxcarbazepine on Bone
Metabolism. Acta Neurol Scand 2009;120(3):170-175.

40. KOO DL, HWANG KJ, HAN SW, et al. Effect of oxcarbazepine on bone mineral density and biochemical
markers of bone metabolism in patients with epilepsy. Epilepsy Res 2014;108(3):442-447.

41. VALIMAKI MJ, TIIHONEN M, LAITINEN K, et al. Bone mineral density measured by dual-energy X-ray
absorptiometry and novel markers of bone-formation and resporption in patients on antiepileptic drugs. J Bone
Min Res 1994;9(5):631-637.

42. VERROTTI A, GRECO R, MORGESE G, CHIARELLI F. Increased bone turnover in epileptic patients treated
with carbamazepine. Ann Neurol 2000;47(3):385-388.

43. ALTAY EE, SERDAROGLU A, TUMER L, GUCUYENER K, HASANOGLU A. Evaluation of bone mineral
metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000;13(7):933-
939.

44. SATO Y, KONDO I, ISHIDA S, et al. Decreased bone mass and increased bone turnover with valproate therapy
in adults with epilepsy. Neurology 2001;57(3):445-449.

45. NICOLAIDOU P, GEORGOULI H, KOTSALIS H, et al. Effects of anticonvulsant therapy on vitamin D status
in children: Prospective monitoring study. J Child Neurol 2006;21(3):205-209.

46. BOLUK A, GUZELIPEK M, SAVLI H, TEMEL I, OZISIK HI, KAYGUSUZ A. The effect of valproate on
bone mineral density in adult epileptic patients. Pharmacolog Res 2004;50(1):93-97.

47. KIM SH, LEE JW, CHOI KG, CHUNG HW, LEE HW. A 6-month longitudinal study of bone mineral density
with antiepileptic drug monotherapy. Epilepsy Behav 2007;10(2):291-295.

48. PACK AM, MORRELL MJ. Adverse effects of antiepileptic drugs on bone structure - Epidemiology,
mechanisms and therapeutic implications. CNS Drugs 2001;15(8):633-642.

49. KOO DL, JOO EY, KIM D, HONG SB. Effects of levetiracetam as a monotherapy on bone mineral density and
biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res 2013;104(1–2):134-139.

50. BERGQVIST AGC, SCHALL JI, STALLINGS VA, ZEMEL BS. Progressive bone mineral content loss in
children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 2008;88(6):1678-1684.